S

SELLAS Life Sciences Group
D

SLS

13.405
USD
-0.45
(-3.25%)
قبل الجلسة·13.550USD+0.145(+1.08%)
حجم التداول
400
الربح لكل سهم
-0
العائد الربحي
-
P/E
-62
حجم السوق
2,707,082,229
أصول ذات صلة المقالات
المزيد

العنوان: SELLAS Life Sciences Group

القطاع: الرعاية الصحية
الصناعة: Biotechnology
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.